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Background: Evidence was found for the effectiveness of virtual reality-based cognitive behavioral therapy (VR-CBT) for
treating paranoia in psychosis, but health-economic evaluations are lacking.
Objective: This study aimed to determine the short-term cost-effectiveness of VR-CBT.
Methods: The health-economic evaluation was embedded in a randomized controlled trial evaluating VR-CBT in 116 patients
with a psychotic disorder suffering from paranoid ideation. The control group (n=58) received treatment as usual (TAU) for
psychotic disorders in accordance with the clinical guidelines. The experimental group (n=58) received TAU complemented with
add-on VR-CBT to reduce paranoid ideation and social avoidance. Data were collected at baseline and at 3 and 6 months
postbaseline. Treatment response was defined as a pre-post improvement of symptoms of at least 20% in social participation
measures. Change in quality-adjusted life years (QALYs) was estimated by using Sanderson et al’s conversion factor to map a
change in the standardized mean difference of Green’s Paranoid Thoughts Scale score on a corresponding change in utility. The
incremental cost-effectiveness ratios were calculated using 5000 bootstraps of seemingly unrelated regression equations of costs
and effects. The cost-effectiveness acceptability curves were graphed for the costs per treatment responder gained and per QALY
gained.
Results: The average mean incremental costs for a treatment responder on social participation ranged between €8079 and
€19,525, with 90.74%-99.74% showing improvement. The average incremental cost per QALY was €48,868 over the 6 months
of follow-up, with 99.98% showing improved QALYs. Sensitivity analyses show costs to be lower when relevant baseline
differences were included in the analysis. Average costs per treatment responder now ranged between €6800 and €16,597, while
the average cost per QALY gained was €42,030.
Conclusions: This study demonstrates that offering VR-CBT to patients with paranoid delusions is an economically viable
approach toward improving patients’ health in a cost-effective manner. Long-term effects need further research.
Trial Registration: International Standard Randomised Controlled Trial Number (ISRCTN) 12929657;
http://www.isrctn.com/ISRCTN12929657
(J Med Internet Res 2020;22(5):e17098) doi: 10.2196/17098
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Introduction
Psychotic disorders impose a large disease burden—morbidity
plus mortality—on the population, and in its wake, substantial
economic costs occur for society and health care systems. The
main drivers of societal costs of schizophrenia are health care
costs and productivity losses, but patients and their families
also incur substantial costs [1]. Low participation rates of
individuals with psychosis in the labor market are an important
cause of productivity losses, while the main contributor to health
care costs are in-patient psychiatric admissions [2]. All in all,
treatment costs of psychotic disorders consume a significant
part of health care budgets in European countries [3].
Paranoid ideation is a common delusion in individuals with a
psychotic disorder. Even when medicinal treatment is successful,
paranoid thoughts and anxiety often remain because of
conditioned avoidance and other acquired safety behaviors in
social situations [4]. Social avoidance hinders recovery in social
participation for patients and keeps unemployment rates as high
as 70%-85% [5,6]. A poor social network contributes to stigma
and a lack of empowerment, resulting in more depressive
symptoms and lower quality of life [7]. A smaller social network
size is associated with more severe overall psychiatric and
negative symptoms [8]. Virtual reality-based cognitive
behavioral therapy (VR-CBT) was found to be an effective
treatment for paranoid ideation in individuals with a psychotic
disorder [9,10]. The use of virtual reality (VR) treatment in
clinical practice is expected to become more widespread as VR
technology becomes more readily available [11]. Therefore,
information on the cost-effectiveness of this kind of treatment
is required. This study was designed to evaluate whether adding
VR-CBT to treatment as usual (TAU) would be effective in
treating paranoid ideation in a cost-effective way with respect
to improving social participation. A trial-based
cost-effectiveness analysis (CEA) was conducted using data
collected in seven outpatient mental health care services in the
Netherlands, comparing add-on VR-CBT with TAU alone. This
paper aims to determine the short-term (ie, 6-month)
cost-effectiveness of VR-CBT from a societal perspective.
Methods
Research Design
The health-economic evaluation was embedded in a randomized
controlled trial evaluating VR-CBT in 116 patients with a
psychotic disorder suffering from paranoid ideation [10]. The
VR-CBT study was a randomized, controlled, single-blind
multicenter trial in two parallel groups, comparing add-on
VR-CBT to TAU alone over a period of 6 months [10]. This
study was approved by the Vrije Universiteit (VU University)
Medical Ethics Committee for mental health service research
and was registered retrospectively at the ISRCTN (International
Standard Randomised Controlled Trial Number) registry
(ISRCTN12929657). The trial protocol is provided elsewhere
[12]. Four virtual social environments—a street, bus, café, and
supermarket—were created with Vizard software (WorldViz).
Within the environment, participants could move by operating
a Logitech F310 Gamepad. They used a Sony HMZ-T1/T2/T3
head-mounted display with a high-definition resolution of 1280
× 720 per eye, a 51.6 diagonal field of view, and a 3DOF (3
degrees of freedom) tracker for head rotation. VR-CBT
therapists were psychologists with at least basic cognitive
behavioral therapy (CBT) training. They received 2 days of
training in VR-CBT. The VR-CBT manual described a
structured treatment plan for all 16 sessions. Therapists were
supervised in a group for 4 hours every month by two VR-CBT
specialists.
Recruitment
Participants were recruited at seven treatment centers in the
Netherlands between April 1, 2014, and December 31, 2015.
To be included, participants had to meet the following criteria:
(1) 18-65 years of age; (2) DSM-IV (Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition) diagnosis of
schizophrenia, schizophreniform disorder, schizoaffective
disorder, delusional disorder, or psychotic disorder not otherwise
specified; (3) suffering from at least mild paranoia, as assessed
by Green’s Paranoid Thoughts Scale (GPTS) (score of >40);
and (4) self-report of avoiding at least one social situation.
Exclusion criteria were as follows: (1) insufficient competency
of Dutch language; (2) IQ below 70; and (3) a concurrent
diagnosis of epilepsy. Assessments were performed at baseline
and at 3 and 6 months postbaseline.
Interventions
All participants continued to receive TAU (ie, antipsychotic
medication, regular contact with a psychiatrist to manage
symptoms, and regular contact with a psychiatric nurse).
Participants in the experimental condition also received
therapist-led VR-CBT. VR-CBT treatment consisted of 16
biweekly sessions of 60 minutes each, using 40 minutes for
exposure and behavioral exercises in virtual social environments.
The therapist used an individual case formulation to help patients
falsify their harm expectancies. No homework exercises were
given between VR-CBT sessions. The treatment protocol, in
Dutch, is available from the corresponding author.
Outcome Measures
Overview
We conducted both a CEA with three measures of improved
social participation as outcome and a cost-utility analysis (CUA)
with quality-adjusted life years (QALYs) gained as outcome.
The outcome measures are described in more detail below.
Social Participation
The outcome of interest in the CEA was social participation.
Social participation was operationalized in three ways: (1)
objective social participation as the amount of time spent with
others, (2) subjective social participation as momentary anxiety,
and (3) subjective social participation as momentary paranoia.
Momentary in this context meant that it was measured in real
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life during social company. All three outcomes were assessed
in real time using the ecological sampling method (ESM). ESM
is a structured diary method in which individuals are asked in
daily life to report their thoughts, feelings, and symptoms, as
well as the appraisal of the present social context. To that end,
all participants carried an electronic device (PsyMate) for the
ESM assessments. The device beeped at semirandom moments
10 times a day over 6 days. At each beep, the device collected
self-assessments on a 7-point Likert scale ranging from 1 (not
at all) to 7 (very). A positive treatment response on each of the
three outcome measures was defined as an improvement of at
least 20% at 6 months follow-up relative to the patient’s baseline
score.
Quality-Adjusted Life Year
The outcome in the CUA was the QALY derived from the GPTS
[13]. The GPTS is an established broad measure of
paranoid-delusional functioning that has long been used as an
outcome measure. This instrument was chosen to be able to
compare results with earlier CUA research on the subject. Mean
GPTS scores at each measurement were first converted into the
standard mean difference (SMD) by dividing the raw mean
change scores by the SD of the GPTS at baseline in the control
condition. In a next step, we used Sanderson et al’s conversion
factor [14] of 0.1835 (ie, the average of 0.209 using a rating
scale and 0.158 using time trade-off), such that a change of 1
standard unit (ie, SMD) on the GPTS is equal to a corresponding
change of 0.18 utility. The utility is a quality of life valuation
and is needed to compute QALY gains in the VR-CBT condition
relative to the TAU condition over the full 6 months between
baseline and follow-up.
Resource Use and Costing
Societal costs were computed by adding (1) the direct medical
costs of health care services use including the costs of
antipsychotic medication and, in the experimental condition,
the additional costs of adjunctive VR-CBT treatment; (2) direct
nonmedical costs of travel; and (3) indirect costs stemming from
lower productivity. For each participant, cost data over the last
3 months were collected at each of three measurement points.
Resource use data, for costing, were collected using the Trimbos
Institute and Institute of Medical Technology Assessment
Questionnaire for Costs Associated with Psychiatric Illness
(TiC-P) [15]. The TiC-P is the most widely used health service
interview in the Netherlands. It consists of questions on the
number of contacts by type of health care provider and questions
on productivity losses. A health service questionnaire is a valid
and reliable method for quantifying costs in trial-based economic
evaluations in health care [16]. A cross-validation sample
comparing TiC-P self-report to electronic patient files showed
all data to be reliable, except for the number of reported sessions
with a psychologist (data available upon request from first
author). Not all patients had understood that they needed to
incorporate the 16 VR-CBT sessions into their TiC-P self-report.
This information was, therefore, 100% cross-checked using
electronic patient files. The main cost driver was admission to
psychiatric hospitals, so the number of days admitted to a
psychiatric hospital was also 100% cross-checked against
electronic patient files and corrected where needed.
Direct medical costs were calculated by multiplying health
service units (eg, sessions, visits, and hospital days) with their
standard economic cost price (see Multimedia Appendix 1). We
also added the medication costs, consisting of antipsychotic and
antidepressant medication. Corresponding costs were calculated
as the cost price per standard daily dose, as reported in the Dutch
Pharmaceutical Compass [17], multiplied by the number of
prescription days, plus the pharmacist’s dispensing costs of €6
per monthly prescription or €12 for a first-time prescription
[18].
Virtual Reality Costs
For VR therapy hardware, software and training costs were
calculated. Total yearly costs for one VR system was €23,995,
according to CleVR BV, a company who builds VR sets. Yearly
costs for training and supervision of the psychologists was
€13,400. Per-patient costs per 16 VR-CBT treatment sessions
was €373.95.
Travel Costs
Travel costs arose when participants had to make return trips
for receiving health care at health services. Travel costs were
computed as the average distance to a health service (7 km)
multiplied by the costs per km (€0.21) [18].
Productivity Costs
Research assistants monitored changes in the participants’work
status at baseline and at 3 and 6 months postbaseline using the
TiC-P. Productivity losses in paid work were calculated
according to the human capital approach [19], reflecting changes
in the contractual number of hours worked per week and
adjusting these for work-loss days arising from sick leave over
the full period of 6 months using gender-specific hourly
productivity costs [18]. Costs were originally expressed in Euros
for the reference year 2014, but indexed to 2015 using the
consumer price index as reported by Statistics Netherlands. In




Following the CONSORT (Consolidated Standards of Reporting
Trials) and CHEERS (Consolidated Health Economic Evaluation
Reporting Standards) guidelines, all our analyses adhered to
the intention-to-treat principle. To that end, missing values were
imputed using multiply imputed chained equations (MICE) for
nonparametric data with M of 100 bootstraps for each
incomplete variable. Baseline variables predictive of effects (ie,
QALYs and treatment response) were used for imputation, such
as baseline data of the variable with missing values, treatment
condition, ethnicity, education, sex, age, and safety behaviors
at baseline. Safety behaviors, such as avoiding eye contact or
escaping from social situations, were measured using the Safety
Behaviour Questionnaire-Persecutory Delusions (SBQ-PD)
[20]. Time spent with others showed a large difference at
baseline despite randomization and was added as covariate in
the CEA where time spent with others was used as the treatment
response outcome of interest.
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Both the CUA and CEA were conducted from the societal
perspective. In each of these analyses, the incremental
cost-effectiveness ratios (ICERs) were calculated as the
between-group cost difference divided by the between-group
effect difference. The ICER is interpreted as the additional costs
per additional unit effect (ie, per additional treatment responder;
per QALY gained). Cost and effect differences were obtained
from seemingly unrelated regression equations of costs and
effects, thus allowing for correlated residuals in the equations.
The seemingly unrelated regression equations (SURE) models
were bootstrapped 5000 times. In each bootstrap step, the mean
cost differences and the mean outcome differences were
computed and these were plotted on the cost-effectiveness plane.
Finally, cost-effectiveness acceptability curves (CEACs) were
graphed. CEACs inform decision makers about the likelihood
that an intervention is deemed cost-effective, given a range of
willingness-to-pay ceilings for gaining 1 QALY and gaining 1
treatment responder. All analyses were conducted in Stata,
version 13.1 (StataCorp).
Sensitivity Analyses
The following sensitivity analyses were carried out. First, a
sensitivity analysis was done including safety behavior at
baseline as a covariate because despite randomization there was
a significant difference at baseline, and it was found to be the
main mediator in reducing paranoid ideation [10]. Second, a
sensitivity analysis was done including psychiatric admission
costs at baseline as a covariate because there was a large
difference between groups at baseline. Third, a sensitivity
analysis was done including both safety behavior at baseline




After providing informed consent, 116 participants agreed to
participate: 58 (50.0%) in the control condition and 58 (50.0%)
in the experimental condition (see Figure 1).
Baseline characteristics of the sample can be found in Table 1.
Results of costs and outcomes can be found in Table 2. A small
group of participants was responsible for a large portion of the
baseline costs, largely related to hospital admissions. The total
days of psychiatric admissions were 233 days at baseline, 101
days posttreatment, and zero days at follow-up for the VR-CBT
group. The total days of psychiatric admissions were 138 days
at baseline, 20 days posttreatment, and 68 days at follow-up for
the TAU group.
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Figure 1. Trial flow diagram. *Specification of participants lost to posttreatment: 6 declined further participation and 2 were lost due to clerical errors
by therapist. ‡Specification of participants lost to follow-up: 9 declined further participation, 1 died of unrelated causes, and 2 were lost due to clerical
errors by therapist. First published in Lancet Psychiatry (Pot-Kolder et al, 2018). VR-CBT: virtual reality-based cognitive behavioral therapy.
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Table 1. Characteristics of the study sample at baseline.
Treatment as usual (TAU) (n=58)VR-CBTa (n=58)Characteristic
42 (72)40 (69)Gender (male), n (%)
39.5 (10.0)36.5 (9.8)Age in years, mean (SD)
25 (43)15 (26)Non-Dutch origin, n (%)
Education, n (%)





49 (85)46 (79)Schizophrenia, n (%)
5 (9)1 (2)Schizoaffective disorder, n (%)
0 (0)1 (2)Delusional disorder, n (%)
4 (7)10 (17)Psychotic disorder (not otherwise specified), n (%)
14.9 (9.5)13.3 (10.6)Duration of illness in years, mean (SD)
Medication use
57 (98)54 (93)Antipsychotics, n (%)
11.0 (8.3)10.5 (6.8)Olanzapine equivalent of prescribed antipsychotic medication (mg/day), mean
(SD)
17 (29)15 (26)Antidepressants, n (%)
5 (9)8 (14)Paid work, n (%)
21.1 (16.0)28.8 (14.2)Safety behaviors, mean (SD)
aVR-CBT: virtual reality-based cognitive behavioral therapy.
bDSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition.
Table 2. Average per-participant costs per 3-month period in Euros for the year 2015 and average outcomes by measurement and condition.
Follow-up (6 months)Posttreatment (3 months)BaselineCosts and outcomes
TAUVR-CBTTAUVR-CBTTAUbVR-CBTa
Costs (€), mean (SD)
1039 (2640)887 (1160)648 (960)3031 (3189)1396 (3146)1918 (5178)Health care costs
24 (16)28 (22)23 (15)60 (34)29 (26)31 (23)Travel costs
102 (588)28 (161)214 (1127)359 (1205)224 (1214)553 (2730)Productivity loss
1165 (2766)943 (1185)885 (1589)3076 (3469)1649 (3570)2502 (6246)Total (societal) costs
Outcomes, mean (SD)
75 (33)67 (33)75 (31)70 (31)77 (31)85 (34)GPTSc paranoia (score)
0.340 (0.273)0.419 (0.209)0.323 (0.266)0.404 (0.226)0.364 (0.266)0.416 (0.256)Time spent with others (proportion)
3.218 (1.388)2.645 (1.095)3.221 (1.495)2.586 (1.089)3.259 (1.484)2.986 (1.120)Momentary anxiety (scored)
3.218 (1.467)2.719 (1.293)3.221 (1.518)2.714 (1.291)3.259 (1.418)3.064 (1.393)Momentary paranoia (scored)
aVR-CBT: virtual reality-based cognitive behavioral therapy.
bTAU: treatment as usual.
cGPTS: Green’s Paranoid Thoughts Scale.
dScores are on a 7-point Likert scale ranging from 1 (not at all) to 7 (very).
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Time Spent With Others
The treatment response rate regarding the time spent with others
was 13 patients out of 58 (22%) in the control group and 24
patients out of 58 (41%) in the experimental group. The
baseline-adjusted between-group difference between the
response rates (ie, the incremental effect) was 0.23, which was
statistically significant (SE=0.076, t113=3.07, 95% CI 0.08-0.38,
P=.003).
Momentary Anxiety
The treatment response rate with regard to momentary anxiety
was 17 patients out of 58 (29%) in the control group and 24
patients out of 58 (41%) in the experimental group. The
between-group difference between the treatment response rates
(ie, incremental effect) was 0.12, but this difference was not
statistically significant (SE=0.089, t114=1.36, 95% CI –0.055
to 0.290, P=.18).
Momentary Paranoia
The treatment response rate in momentary GPTS paranoia was
11 patients out of 58 (19%) in the control group and 28 patients
out of 58 (48%) in the experimental group. The between-group
difference in the response rates was 0.29 and was statistically
significant (SE=0.0841, t114=3.48, 95% CI 0.126-0.460, P=.001).
Quality-Adjusted Life Years
The SMD of GPTS paranoia was 0.523, which was statistically
significant (SE=0.120, t114=4.37, 95% CI 0.285-0.760, P<.001).
Using Sanderson et al’s conversion factor [14] of 0.1835 and
taking into account a follow-up period of half a year, this
became a QALY gain of 0.048 (0.523 × 0.1835 × 0.5) favoring
the VR-CBT condition and this was statistically significant
(SE=0.011, t114=4.37, 95% CI 0.026-0.069, P<.001).
Incremental Costs
Incremental Health Care Costs
As can be seen in Table 2, the average per-patient health care
costs in the TAU group was €1396 at baseline, €648 at
posttreatment, and €1039 at follow-up. The average per-patient
health care costs in the VR-CBT group was €1918 at baseline,
€3031 at posttreatment, and €887 at follow-up. This includes
€373.95 per patient for VR-related costs included in the
posttreatment costs.
The cumulative costs per patient between baseline and
follow-up, including the costs of VR-CBT, were €1686 and
€3917 in the TAU and VR-CBT conditions, respectively. The
between-group difference was €2231 (€3917–€1686) and was
statistically significant (SE=663, t114=3.36, P=.001) when not
adjusted for the initial cost difference between the conditions
at baseline. After adjustment for baseline costs, the incremental
health care costs became slightly less at €2170 and retained
statistical significance (SE=661, t113=3.28, P=.001).
Incremental Costs Stemming From Productivity Losses
A total of 11.2% (13/116) of the participants had paid work.
The average costs stemming from productivity losses per person
for the TAU group was €224 at baseline, €214 at posttreatment,
and €104 at follow-up. The average costs stemming from
productivity losses per person for the VR-CBT group was €553
at baseline, €359 posttreatment and €28 at follow-up. The
cumulative costs per patient between baseline and follow-up
were €317 and €387 in the TAU and VR-CBT conditions,
respectively. The between-group difference was €70
(€387–€317) and was not statistically significant (SE=274,
t114=–0.26, P=.80).
Travel Costs
The average costs stemming from travel per person for the TAU
group was €29 at baseline, €23 at posttreatment, and €24 at
follow-up. The average travel costs per person for the VR-CBT
group was €31 at baseline, €60 at posttreatment, and €28 at
follow-up. The cumulative travel costs per patient between
baseline and follow-up were €47 and €88 in the TAU and
VR-CBT conditions, respectively. The between-group difference
was €41 (€88–€47) and was statistically significant (SE=6,
t114=–6.73, P<.001).
Incremental Costs From the Societal Perspective
The cumulative societal costs per patient between baseline and
follow-up were €2050 and €4393 in the TAU and VR-CBT
conditions, respectively. The between-group difference was
€2343 (€4293–€2050) and was statistically significant (SE=747,
t114=–3.14, P=.002).
Incremental Cost-Effectiveness Ratios From the Societal
Perspective
The mean incremental costs for a positive treatment responder
was as follows:
1. Time spent with others: €2343/0.23=€10,069.
2. Momentary anxiety: €2343/0.12=€19,525.
3. Momentary paranoia: €2343/0.29=€8079.
4. The mean incremental cost per QALY:
€2343/0.048=€48,868.
Figures 2 to 4 depict the distribution of the 5000 bootstrapped
ICERs over the cost-effectiveness plane for each of the social
participation measures. Figure 2 depicts time spent with others,
the plane illustrates 99.70% of the ICERs fall in the northeast
quadrant, indicating that more QALYs are gained for higher
costs. Figure 3 depicts momentary anxiety, the plane illustrates
90.74% of the ICERs fall in the northeast quadrant, indicating
that more QALYs are gained for higher costs. Figure 4 depicts
momentary paranoia, the plane illustrates 99.74% of the ICERs
fall in the northeast quadrant, indicating that more QALYs are
gained for higher costs.
Figure 5 depicts the distribution of the bootstrapped ICERs over
the cost-effectiveness plane, with the vast majority of the ICERs
in the northeast quadrant, indicating that more QALYs are
gained but for higher costs, while 0.02% of the simulated ICERs
fall in the southeast quadrant (ie, QALY gains for lower costs)
for the VR-CBT group compared with the TAU group.
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Figure 2. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for time spent with others.
Figure 3. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for momentary anxiety.
Figure 4. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for momentary paranoia.
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Figure 5. Cost-effectiveness plane and willingness to pay (WTP) acceptability curve for quality-adjusted life year (QALY) gain (costs per QALY
gained) after 6 months.
Acceptability
The mean incremental cost per QALY was €48,868. When
looking at the acceptability curve in Figure 5, a higher
probability that the VR-CBT intervention is deemed
cost-effective can also be calculated. For an 80% certainty of
cost-effectiveness, the incremental cost for gaining 1 QALY is
€66,161, which falls well below the willingness-to-pay ceiling
of €80,000 in the Netherlands for a severely disabling condition,
such as schizophrenia characterized by paranoid delusions [21].
Looking at the three treatment responses, at 50% probability of
being cost-effective, the costs are as mentioned: time spent with
others, €10,069; momentary anxiety, €19,525; and momentary
paranoia, €8079. Supposing that a decision maker needs an
80% certainty, time spent with others will have to be valued at
€14,293 per treatment responder; momentary anxiety at €50,000;
and momentary paranoia at €11,342.
Sensitivity Analysis
When including safety behavior at baseline as a covariate, the
incremental costs per treatment responder on time spent with
others became €9136; momentary anxiety became €17,535; and
momentary paranoia became €7219. When including safety
behavior at baseline as a covariate, the incremental costs per
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QALY gained became €44,597. Overall, incremental costs were
somewhat lower when the baseline difference of safety
behaviors was included in the analysis.
When including psychiatric admission costs at baseline as a
covariate, the incremental costs per treatment responder on time
spent with others became €9729; momentary anxiety became
€18,879; and momentary paranoia became €7750. When
including psychiatric admission at baseline as a covariate, the
incremental costs per QALY gained became €47,308. Overall,
incremental costs were somewhat lower when the baseline
difference of psychiatric admission costs was included in the
analysis.
When including both psychiatric admission costs at baseline
and safety behavior at baseline as covariates, the incremental
costs per treatment responder on time spent with others became
€8592; momentary anxiety became €16,597; and momentary
paranoia became €6800. When including both psychiatric
admission costs and safety behavior at baseline as covariates,
the incremental costs per QALY gained became €42,030.
Overall, incremental costs were lower when the baseline
differences of both safety behaviors and psychiatric admission
costs were included in the analysis.
Discussion
Principal Findings
This study aimed to get an impression of short-term
cost-effectiveness of VR-CBT for patients with paranoid
delusions in comparison to TAU from a societal perspective.
Data were collected 6 months after baseline at follow-up. Costs
per treatment responder gained were estimated to be between
€8079 and €19,525 for different aspects of social participation,
with between 90.74% and 99.74% showing improvement. Cost
per QALY gained at follow-up was estimated to be €48,868
with 99.98% showing improved QALYs. Sensitivity analyses
showed costs to be lower when baseline differences in both
safety behavior and psychiatric admission costs were included
in the analysis. Costs per treatment responder gained were then
estimated to be between €6800 and €16,597, with cost per
QALY gained at €42,030.
Results in Context
How much a society values solidarity with people burdened by
disease will determine if guidelines are translated to actual
treatment of patients. While the VR-CBT treatment condition
is more expensive than TAU only, that was to be expected, as
the aim was to add to existing treatment. Results show that this
addition improves social participation for people with a
psychotic disorder suffering from paranoid ideation. We see
this improvement for time spent with others, momentary
paranoia, momentary anxiety, and paranoid ideation, via the
GPTS.
Engaging in psychological therapy is challenging for many
patients suffering from paranoid ideation and treatment results
vary. There are several aspects that favor VR treatment.
Person-specific behavioral exposure is an important part of
increasing treatment effect [22], which is exactly what the
interactive VR social environments offer. Patients themselves
also prefer VR over in vivo exposure treatment [23] and VR
improves treatment motivation for patients [24].
Interestingly, during the follow-up we see that the VR-CBT
group resulted in decreased health care costs and decreased
costs due to productivity loss compared to the TAU-only group.
There were no psychiatric admission days at follow-up for the
VR-CBT group. To determine whether this was a coincidence
or a trend, a much longer follow-up period is needed. Short-term
societal costs were between €8079 and €19,525 for a positive
treatment response. A disability weight of zero represents no
loss of health and a weight of 1 represents health loss equivalent
to death [25]. In the Netherlands, the willingness to pay for
gaining a QALY ranges between €20,000 and €80,000 but
differs per disease [26]. For a severely disabling disease such
as schizophrenia, which according to the Global Burden of
Disease study 2010 has a disability weight of 0.76, the
willingness to pay is €80,000 [21,26]. In this context, the
VR-CBT treatment that has an ICER of €48,868 per QALY
gained can be regarded as acceptable from the cost-effectiveness
point of view.
Limitations
The study has several limitations. First, data were collected only
6 months postbaseline. Any longer-term effects and costs are
unknown. There are indications that cost-effectiveness for
treatment of psychotic symptoms improves with time [27] as
health benefits continue. Second, minimal treatment response
was set at a 20% symptom reduction. A 20% symptom reduction
after just 8 weeks of therapy is clinically relevant in a patient
group with an average duration of illness of 14 years with
persistently high problematic isolation. Third, VR-CBT was
compared to TAU only. The next step would be to compare
VR-CBT directly to CBT, which is the current gold standard,
as CBT without VR also results in additional costs to TAU.
There are, however, also indications that VR-CBT could have
positive results in fewer sessions compared to CBT [9].
Comparing VR-CBT directly to CBT also allows for the study
of presumed benefits of VR therapy, such as better engagement
and the ecological validity of VR on outcome effects. Such a
study comparing VR-CBT and CBT on time to response and
costs is currently ongoing (Netherlands Trial Register number
NL7758). A final limitation was that QALYs were not measured
directly. As the EQ-5D (European Quality of Life Five
Dimension Scale) was not administered, QALYs were calculated
using Sanderson et al’s conversion factor [14]. Future research
needs to include the EQ-5D for direct measurement.
Conclusions
This study found VR-CBT to be cost-effective in the short term
from a societal perspective. However, the effect of additional
VR-CBT sessions and long-term effects need to be determined
while using direct measurement of QALYs.
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Direct medical costs. Prices are from 2015 and are in Euros. *8 (sessions) × 2.5 (hours) × 2 (therapists) × 112 (Euros per
contact-hour) / 8 (participants) = Є560. WRAP: Wellness Recovery Action Plan.
[PNG File , 60 KB-Multimedia Appendix 1]
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3DOF: 3 degrees of freedom
CBT: cognitive behavioral therapy
CEA: cost-effectiveness analysis
CEAC: cost-effectiveness acceptability curve
CHEERS: Consolidated Health Economic Evaluation Reporting Standards
CONSORT: Consolidated Standards of Reporting Trials
CUA: cost-utility analysis
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition
EQ-5D: European Quality of Life Five Dimension Scale
ESM: ecological sampling method
GPTS: Green’s Paranoid Thoughts Scale
ICER: incremental cost-effectiveness ratio
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MICE: multiply imputed chained equations
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SMD: standard mean difference
SURE: seemingly unrelated regression equations
TAU: treatment as usual
TiC-P: Trimbos Institute and Institute of Medical Technology Assessment Questionnaire for Costs Associated
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